Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTE: Glatiramer Acetate 40 mg vs 20 mg in RRMS
NCT00337779Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2006
- Primary completion
- Oct 2008
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS), sponsored by Teva Pharmaceutical Industries Ltd.. Started Aug 2006; status: completed.
02
Drugs
glatiramer acetate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00337779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00337779.